References
- Macdougall IC. Erythropoiesis-stimulating agents in chronic kidney disease. In: Turner N, Goldsmith DJ, Winearls CG, et al. editors. Oxford textbook of clinical nephrology. Oxford: Oxford University Press; 2015.
- Palmer SC, Saglimbene V, Craig JC, et al. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014 Mar 31;3:CD009297.
- Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs. 2008;68:1139–1156.
- Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996 Jul 26;273(5274):458–464.
- Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361(19):1848–1855.
- Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006 Oct;34(10):1303–1311.
- Highlights of prescribing information for Omontys. Food and Drug Administration; 2012 [cited 2016 Jan 29]. Available from:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s000lbl.pdf in
- Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011;6:2579–2586.
- Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307–319.
- Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013;368(4):320–332.
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Withdrawal Assessment report for Omontys. EMA/419554/2013; [ updated 2013 Apr 25; cited 2016 Jan 25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2013/09/WC500148933.pdf
- Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–1155.
- Weinhandl ED, Gilbertson DT, Collins AJ, et al. Relative safety of peginesatide and epoetin alfa. Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1003–1011.
- Bennett CL, Jacob S, Hymes J, et al. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014 May 22; 370(21):2055–2056.
- Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008 Aug;98(8):1366–1371.
- Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–1408.
- Health Sciences Authority of Singapore. Contraindication of subcutaneous administration of Eprex® (epoetin alfa) in Singapore in chronic kidney disease patients; [ updated 2013 Dec 31; cited 2016 May 9]. Available from: http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2013/contraindication_of.html
- Lincoff AM, Mehran R, Povsic TJ, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016;387(10016):349–356. doi:10.1016/S0140-6736(15)00515-2.
- Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2016 Jan;89(1):28–39.
- Macdougall IC, Casadevall N, Locatelli F, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30(3):451–460.
- Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676.
- Weaver JL, Boyne M, Pang E, et al. Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog. Toxicol Appl Pharmacol. 2015;287:246–252.
- Kotarek J, Stuart C, De Paoli SH, et al. Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events. J Pharm Sci. 2016;105(3):1023–1027.